Key takeaways
- Statins are extremely efficient at stopping atherosclerotic heart problems however choosing which sufferers are most in danger and may obtain statins may be difficult.
- The CorCal Outcomes trial in contrast whether or not statin initiation based mostly on the affected person’s coronary artery calcium measurement might cut back cardiovascular occasions vs. conventional danger factor-based evaluation.
- No distinction was noticed in main cardiovascular occasions with coronary artery calcium or danger issue evaluation.
- Cardiovascular occasions general have been decrease than anticipated, limiting the trial’s energy, however insights may very well be used to plan additional research to enhance on present danger evaluation.
Munich, Germany – 31 August 2026: There was no distinction in main cardiovascular occasions when statin initiation was based mostly on coronary artery calcium in contrast with conventional danger issue evaluation, based on outcomes introduced in a Sizzling Line session in the present day at ESC Congress 2026.[1]
Cardiovascular ailments proceed to be the main explanation for morbidity and mortality globally. The main contributor to the heart problems burden is atherosclerotic heart problems (ASCVD), which incorporates coronary artery illness and ischaemic stroke. Key modifiable danger components for ASCVD embrace smoking, diabetes, hypertension and excessive levels of cholesterol.
“For a lot too many sufferers, the primary symptom of ASCVD is a coronary heart assault,” mentioned Physician Joseph B Muhlestein from the Intermountain Medical Heart, Murray, USA, the Principal Investigator of the CorCal Outcomes trial. “Statins have been proven to be extremely efficient within the prevention of ASCVD; nevertheless, there’s a main hole in danger evaluation, statin initiation and statin persistence.” He famous that for a excessive proportion of people, particularly youthful people with a primary coronary heart assault, present danger evaluation instruments wouldn’t have recognized them as being at sufficiently excessive danger to warrant statin remedy.
The CorCal Outcomes trial in contrast two strategies for choosing sufferers to obtain statin remedy to stop a primary cardiovascular occasion: the pooled cohort equations (PCE), that are based mostly on conventional danger components, and coronary artery calcium (CAC) measurement, which is an evaluation of coronary plaque burden carried out utilizing a computed tomography (CT) scan.
Sufferers with out identified ASCVD, diabetes or prior statin remedy who have been registered with the Canyons and Desert areas of Intermountain Well being Care, USA, have been invited to take part. Eligible sufferers have been randomised (1:1) to obtain steering on statin initiation based mostly on both their PCE danger rating or their CAC rating. The members and their physicians obtained a protocol-directed advice on whether or not to provoke statin remedy based mostly on the outcomes they usually made the ultimate remedy choices. The first endpoint was main cardiovascular occasions (MACE; all-cause mortality, myocardial infarction, stroke and arterial revascularisation). The examine inhabitants comprised 5,772 sufferers who had a imply age of 64 years and 51% have been ladies.
After 4.2 years of follow-up, there was no distinction in MACE between the teams. MACE occurred in 2.7% of sufferers in each teams and the noninferiority criterion was not met (hazard ratio 0.99; 95% confidence interval 0.71 to 1.38; p=0.045 for noninferiority).
The researchers discovered that sufferers randomised to the PCE group obtained a advice to provoke statins greater than thrice as regularly as these within the CAC group. Nevertheless, sufferers who have been really useful a statin based mostly on their CAC rating have been way more adherent with their treatment than these within the PCE group (62% vs. 23%).
“The ability of the examine to detect a distinction was diminished by the lower-than-expected occasion charges and we didn’t reveal noninferiority between the teams,” mentioned Physician Muhlestein, who concluded: “The examine did present essential hypothesis-generating insights into the effectivity of statin initiation and adherence when choices are based mostly on CAC scoring. Taken collectively, our knowledge may very well be used to plan a further well-powered randomised trial evaluating CAC with present danger factor-based algorithms.”
The 2025 Centered Replace of the 2019 ESC/EAS Tips for the administration of dyslipidaemias embrace a advice that the presence of subclinical atherosclerosis by elevated CAC rating, if measured, must be thought-about as a danger modifier in people at reasonable danger or people round treatment-decision thresholds.[2]
ENDS
